Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camostat mesylate in chronic pancreatitis
NCT02693093Phase 2Completed
- Sponsor
- Kangen Pharmaceuticals Co. Ltd.
- Start
- Feb 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of camostat mesilate in chronic pancreatitis (CP) (4 arms), sponsored by Kangen Pharmaceuticals Co. Ltd. Primary endpoints: Average daily worst pain intensity score at 4 weeks, Pharmacokinetic profile for FOY251 and GBA and 1 more. Started Feb 2016; status: completed.
02
Drugs
camostat mesilate
03
Conditions
chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT02693093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693093.